Cargando…
The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification
BACKGROUND: Chuanxiong Rhizoma (CR) is a common traditional Chinese medicine (TCM) that has been widely used in the treatment of spinal cord injury (SCI). However, the underlying molecular mechanism of CR is still largely unknown. This study was designed to explore the bioactive components and the m...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350674/ https://www.ncbi.nlm.nih.gov/pubmed/34430586 http://dx.doi.org/10.21037/atm-21-2529 |
_version_ | 1783735819439177728 |
---|---|
author | Tao, Bo Wang, Qi Cao, Jiangang Yasen, Yimingjiang Ma, Lei Sun, Chao Shang, Jun Feng, Shiqing |
author_facet | Tao, Bo Wang, Qi Cao, Jiangang Yasen, Yimingjiang Ma, Lei Sun, Chao Shang, Jun Feng, Shiqing |
author_sort | Tao, Bo |
collection | PubMed |
description | BACKGROUND: Chuanxiong Rhizoma (CR) is a common traditional Chinese medicine (TCM) that has been widely used in the treatment of spinal cord injury (SCI). However, the underlying molecular mechanism of CR is still largely unknown. This study was designed to explore the bioactive components and the mechanism of CR in treating SCI based on a network pharmacology approach and experimental validation. METHODS: First, the active compounds and related target genes in CR were screened from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Subsequently, the corresponding target genes of SCI were collected by the Therapeutic Target Database (TTD) and GeneCards database. A protein-protein interaction (PPI) network was constructed using the STRING database. Furthermore, GO function and KEGG enrichment analysis of the targets were analyzed using DAVID tools. Subsequently, the AutoDock software for molecular docking was adopted to verify the above network pharmacology analysis results between the active components and key targets. Finally, an SCI rat model animal validation experiment was assessed to verify the reliability of the network pharmacology results. RESULTS: There were 7 active ingredients identified in CR and 246 SCI-related targets were collected. Then, 4 core nodes (ALB, AKT1, MAPK1, and EGFR) were discerned via construction of a PPI network of 111 common targets. The KEGG enrichment analysis results indicated that the Ras signaling pathway, estrogen signaling pathway, and vascular endothelial growth factor (VEGF) signaling pathway were enriched in the development of SCI. The results of molecular docking demonstrated that the effects of CR have a strong affinity with the 4 pivotal targets. Experimental validation in a rat model showed that CR could effectively improve the recovery of motor function and mechanical pain threshold after SCI. CONCLUSIONS: In summary, it revealed the mechanism of CR treatment for SCI involve active ingredients, targets and signaling pathways, providing a scientific basis for future investigations into the mechanism underlying CR treating for SCI. |
format | Online Article Text |
id | pubmed-8350674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-83506742021-08-23 The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification Tao, Bo Wang, Qi Cao, Jiangang Yasen, Yimingjiang Ma, Lei Sun, Chao Shang, Jun Feng, Shiqing Ann Transl Med Original Article BACKGROUND: Chuanxiong Rhizoma (CR) is a common traditional Chinese medicine (TCM) that has been widely used in the treatment of spinal cord injury (SCI). However, the underlying molecular mechanism of CR is still largely unknown. This study was designed to explore the bioactive components and the mechanism of CR in treating SCI based on a network pharmacology approach and experimental validation. METHODS: First, the active compounds and related target genes in CR were screened from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Subsequently, the corresponding target genes of SCI were collected by the Therapeutic Target Database (TTD) and GeneCards database. A protein-protein interaction (PPI) network was constructed using the STRING database. Furthermore, GO function and KEGG enrichment analysis of the targets were analyzed using DAVID tools. Subsequently, the AutoDock software for molecular docking was adopted to verify the above network pharmacology analysis results between the active components and key targets. Finally, an SCI rat model animal validation experiment was assessed to verify the reliability of the network pharmacology results. RESULTS: There were 7 active ingredients identified in CR and 246 SCI-related targets were collected. Then, 4 core nodes (ALB, AKT1, MAPK1, and EGFR) were discerned via construction of a PPI network of 111 common targets. The KEGG enrichment analysis results indicated that the Ras signaling pathway, estrogen signaling pathway, and vascular endothelial growth factor (VEGF) signaling pathway were enriched in the development of SCI. The results of molecular docking demonstrated that the effects of CR have a strong affinity with the 4 pivotal targets. Experimental validation in a rat model showed that CR could effectively improve the recovery of motor function and mechanical pain threshold after SCI. CONCLUSIONS: In summary, it revealed the mechanism of CR treatment for SCI involve active ingredients, targets and signaling pathways, providing a scientific basis for future investigations into the mechanism underlying CR treating for SCI. AME Publishing Company 2021-07 /pmc/articles/PMC8350674/ /pubmed/34430586 http://dx.doi.org/10.21037/atm-21-2529 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Tao, Bo Wang, Qi Cao, Jiangang Yasen, Yimingjiang Ma, Lei Sun, Chao Shang, Jun Feng, Shiqing The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification |
title | The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification |
title_full | The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification |
title_fullStr | The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification |
title_full_unstemmed | The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification |
title_short | The mechanisms of Chuanxiong Rhizoma in treating spinal cord injury based on network pharmacology and experimental verification |
title_sort | mechanisms of chuanxiong rhizoma in treating spinal cord injury based on network pharmacology and experimental verification |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350674/ https://www.ncbi.nlm.nih.gov/pubmed/34430586 http://dx.doi.org/10.21037/atm-21-2529 |
work_keys_str_mv | AT taobo themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT wangqi themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT caojiangang themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT yasenyimingjiang themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT malei themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT sunchao themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT shangjun themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT fengshiqing themechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT taobo mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT wangqi mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT caojiangang mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT yasenyimingjiang mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT malei mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT sunchao mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT shangjun mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification AT fengshiqing mechanismsofchuanxiongrhizomaintreatingspinalcordinjurybasedonnetworkpharmacologyandexperimentalverification |